A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A

PHASE3CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

March 27, 2023

Primary Completion Date

September 5, 2024

Study Completion Date

September 5, 2024

Conditions
Hemophilia A
Interventions
BIOLOGICAL

Adynovate

Adynovate was injected intravenously using an appropriately sized syringe as a bolus infusion over a period of less than or equal to (\<=) 5 minutes (maximum infusion rate, 10 milliliters per minute \[mL/min\]).

Trial Locations (12)

Unknown

Beijing Children's Hospital, Capital Medical University, Beijing

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing

Xiangya Hospital of Central South University, Changsha

Fujian Medical University Union Hospital, Fuzhou

Nanfang Hospital Southern Medical University, Guangzhou

Anhui Province Hospital, Hefei

Jinan Central Hospital, Jinan

Shenzhen Second People's Hospital, Shenzhen

The First Affiliated Hospital of Soochow University, Suzhou

Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin

Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY